EP Patent

EP2651405A2 — Casein kinase 1 (ck1 ) inhibitors

Assigned to Proteome Sciences PLC · Expires 2013-10-23 · 13y expired

What this patent protects

The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

USPTO Abstract

The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP2651405A2
Jurisdiction
EP
Classification
—
Expires
2013-10-23
Drug substance claim
No
Drug product claim
No
Assignee
Proteome Sciences PLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.